Dialysis modality, humoral response to vaccine, and SARS‐CoV‐2 infection risk: Comparative prospective evaluation

Abstract

AbstractBackgroundCOVID‐19 vaccinations have a central role in decreasing severe SARS‐CoV‐2 disease complications. This study investigated the long‐term humoral immune response to BNT162b2 vaccine among hemodialysis (HD) versus peritoneal dialysis (PD) patients, and their relative risk for COVID‐19 infection.MethodsThis prospective, observational study included maintenance HD and PD patients who had received at least two BNT162b2 vaccine doses. Levels of antibodies targeting SARS‐CoV‐2 spike protein were measured 6 and 12 months after the first vaccine dose, and 2–3 weeks after the third and fourth vaccine doses. Patients were divided according to dialysis modality (HD or PD). Humoral response was evaluated at different time points among different vaccine regimens (two vs. three vs. four doses of vaccine). An adjusted multivariate model was used to assess cumulative risk for SARS‐CoV‐2 infection.ResultsEighty‐seven HD and 36 PD patients were included. Among them, 106 (86%) received at least three vaccine doses. Both HD and PD patients demonstrated marked increases in humoral response 2–3 weeks after the third dose (mean anti‐S antibody increased from 452 ± 501 AU/mL to 19,556 ± 14,949 AU/mL, p < 0.001). By 6 months after the third dose, antibody titers had declined significantly (mean anti‐S antibody 9841 ± 10,493 AU/mL, p < 0.001). HD patients had higher risk for SARS‐CoV‐2 infection than PD patients (OR 4.4 [95% CI 1.4–13.6], p = 0.006). In multivariate analysis, the most important predictor for SARS‐CoV‐2 infection was dialysis modality.ConclusionThis study found a high antibody response rate after the third and fourth doses of BNT162b2 vaccine among dialysis patients. Hemodialysis as dialysis modality is an important predictor of COVID‐19 infection, despite similar humoral responses to vaccine in peritoneal dialysis.